Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

New agency

- PMLiVE

Is omnichannel right for rare diseases?

By Emma Warnants and Chloe Zentai

- PMLiVE

Creating a future with more clinical empathy

By Julia Crawford

AMICULUM supports Lung Cancer Europe’s ‘Get Checked!’ campaign for Lung Cancer Awareness Month

By Leyna Prince

Amiculum

- PMLiVE

Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

The neurological disorder affects approximately 2.9 million people globally

EU flag

CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

- PMLiVE

Gilead appoints Dietmar Berger as chief medical officer

Berger most recently served as chief medical officer and global head of development at Sanofi

- PMLiVE

The need for a human touch in an AI world

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice

- PMLiVE

Best practices in linguistic validation of clinical outcomes assessments

By Christelle Giroudet and Ana Alvarez

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

- PMLiVE

Tackling the growing burden of chronic obstructive pulmonary disease in the UK

Iona Everson from PMGroup spoke to John Forni, Country Medical Director at Sanofi UK & Ireland, about the escalating challenges of treating chronic obstructive pulmonary disease (COPD) in the UK...

- PMLiVE

Over 40 years of Ipsen in the UK: resilience and leadership in the life sciences sector

By Ioana Parsons

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links